In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020). This evidence concerns the gene HRAS and head and neck cancer.